Heart Attack Diagnostics Market Summary

The global heart attack diagnostics market size was valued at USD 10.75 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2030. This notable growth is primarily driven by increasing risk factors associated with heart attacks, which are largely attributed to unhealthy lifestyle habits such as poor diet, smoking, high body mass index (BMI), physical inactivity, and the growing prevalence of chronic health conditions including diabetes and hypertension. These contributing elements collectively create a higher demand for early and accurate diagnostic solutions in cardiovascular care.

A heart attack, medically referred to as myocardial infarction, occurs when specific regions of the heart muscle are deprived of oxygen. This oxygen deficiency is typically the result of blocked blood flow to the heart, often caused by a buildup of plaque or clots in the coronary arteries. Prompt and precise diagnosis of such events is crucial for effective treatment and better patient outcomes, thereby fueling the demand for innovative and reliable diagnostic tools.

According to the World Heart Report, cardiovascular diseases remain a critical global health concern, impacting over 500 million individuals worldwide. Alarmingly, these conditions led to 20.5 million deaths in 2021, representing nearly one-third of all global deaths and marking a sharp increase from the estimated 121 million deaths attributed to cardiovascular diseases (CVDs). These diseases affect both the heart and the blood vessels and arise from a variety of factors—socio-economic, metabolic, behavioral, and environmental. These include high blood pressure, poor diet, high cholesterol, diabetes, air pollution, obesity, tobacco use, kidney disease, sedentary lifestyle, excessive alcohol intake, and mental stress.

Key Market Trends & Insights

• In 2023, the blood tests segment dominated the market by capturing a substantial revenue share of 54.1%. A major factor contributing to this dominance is the clinical importance of biomarkers like Troponin T, a cardiac-specific protein released into the bloodstream following heart muscle damage. Elevated levels of this protein serve as a crucial indicator in confirming a heart attack, which significantly boosts the adoption of blood-based diagnostics.
• The hospital segment accounted for 21.5% of the market share in 2023. This dominance is largely due to the high volume of surgical interventions and diagnostic procedures performed in hospitals, along with the widespread availability of hospital facilities across the globe. According to available data, more than 290,000 adults in the United States suffer from in-hospital cardiac arrests annually, emphasizing the importance of effective diagnostic capabilities in these settings.
• The ambulatory segment is projected to experience robust growth at a CAGR of 10.6% throughout the forecast period. This surge is fueled by the growing preference for quicker, more convenient diagnostic methods, particularly for non-critical and early-stage cases. Technological advancements in portable and easy-to-use diagnostic equipment are facilitating the expansion of ambulatory services as a practical alternative to hospital-based testing.
• North America emerged as the largest regional market for heart attack diagnostics in 2023, accounting for a revenue share of 38.5%. This is attributed to the high incidence of cardiovascular diseases in countries such as the U.S. and Canada, along with the presence of well-established healthcare infrastructure, high healthcare expenditure, and substantial investment in diagnostic technology development.
• In the United States, the heart attack diagnostics market is projected to grow at a significant CAGR of 8.2% during the forecast period. A recent study by the Centers for Disease Control and Prevention (CDC) indicates that one person experiences a heart attack every 40 seconds in the country. Furthermore, heart attack treatment ranks among the most expensive medical services in the American healthcare system, thereby increasing demand for cost-effective and efficient diagnostic tools.
• The European heart attack diagnostics market was valued at USD 3.1 billion in 2023 and is expected to register a CAGR of 7.4% from 2024 to 2030. The market growth in the region is being supported by improved access to healthcare services, growing awareness regarding preventive diagnostics, and increased governmental initiatives to combat cardiovascular disease-related mortality.
• In the Asia Pacific region, the heart attack diagnostics market is anticipated to grow steadily at a CAGR of 10.0% over the forecast period. The significant burden of cardiovascular diseases in highly populated nations such as India and China, combined with improving healthcare infrastructure and rising awareness, is expected to be a key contributor to this regional market expansion.

Order a free sample PDF of the Heart Attack Diagnostics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 10.75 billion
• 2030 Projected Market Size: USD 18.52 billion
• CAGR (2024-2030): 8.2%
• North America: Largest market in 2023

Key Players

• GE Healthcare
• Hitachi Corporation
• Koninklijke Philips NV
• Midmark Corporation
• F Hoffmann-La Roche Ltd
• Schiller AG
• Siemens Healthineers
• Toshiba Corporation
• Welch Allyn Inc
• Astrazenca PLC

Browse Horizon Databook on Heart Attack Diagnostics Market – Global Heart Attack Diagnostics Size & Outlook

Conclusion

The global heart attack diagnostics market is set to witness steady growth driven by escalating cardiovascular disease prevalence, poor lifestyle choices, and increasing awareness of early diagnosis. With strong demand for accurate and rapid diagnostic methods, especially blood-based tests like Troponin T, the market continues to evolve. Hospitals remain pivotal, while ambulatory settings grow due to technological convenience. North America leads due to advanced infrastructure, while Asia Pacific exhibits the fastest growth. Rising healthcare investments, portable diagnostics, and global health initiatives are strengthening market foundations. Collectively, these dynamics position the heart attack diagnostics market for sustained innovation and expansion through 2030.